Author(s): Zucman D, Truchis Pd, Majerholc C, Stegman S, CaillatZucman S
Abstract Share this page
Abstract The association of human leukocyte antigen-B*5701 with abacavir hypersensitivity varies depending on ethnic origin. We confirmed the high specificity of B*5701 in the ethnically mixed French population and used a rapid and inexpensive polymerase chain reaction strategy to evaluate the predictiveness of B*5701 screening. The incidence of hypersensitivity decreased from 12\% before screening to 0\% after screening, and the rate of unwarranted interruptions of abacavir therapy decreased from 10.2\% to 0.73\%. We therefore recommend the implementation of this cost-effective screen before treatment with abacavir.
This article was published in J Acquir Immune Defic Syndr
and referenced in Journal of Pharmacogenomics & Pharmacoproteomics